- Home
- CMPS vs IOVA Comparison
CMPS vs IOVA Comparison
Compare CMPS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | IOVA |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CMPS | IOVA |
|---|---|---|
| Price | $11.28 | $14.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 10 |
| Target Price | ★ $23.75 | $14.40 |
| AVG Volume (30 Days) | 2.4M | ★ 14.0M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $56.63 |
| Revenue Next Year | N/A | $42.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.88 | $1.76 |
| 52 Week High | $15.87 | $15.06 |
Technical Indicators
Market Signals| Indicator | CMPS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 70.94 |
| Support Level | $10.66 | $3.57 |
| Resistance Level | $14.74 | $15.06 |
| Average True Range (ATR) | 0.57 | 0.77 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 6.05 | 86.25 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.